Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-06-09
2010-10-05
Helms, Larry R. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S130100
Reexamination Certificate
active
07807379
ABSTRACT:
The present invention describes a method for determining whether an individual is likely to suffer from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
REFERENCES:
patent: 5324634 (1994-06-01), Zucker
patent: 5356817 (1994-10-01), Cole
patent: 5643752 (1997-07-01), Hawkins et al.
patent: 7108983 (2006-09-01), Holten-Andersen et al.
patent: 2002/0012950 (2002-01-01), Nielsen et al.
patent: 2003/0082652 (2003-05-01), Holten-Andersen et al.
patent: 2004/0014190 (2004-01-01), Lawrence et al.
patent: 2004/0105862 (2004-06-01), Pan et al.
patent: 2004/0157278 (2004-08-01), Astle et al.
patent: 2006/0014224 (2006-01-01), Brunner et al.
patent: 2006/0154245 (2006-07-01), Hessel et al.
patent: 2008/0261246 (2008-10-01), Holten Andersen
patent: 2009/0035794 (2009-02-01), Hessel
patent: 1236102 (1999-11-01), None
patent: PA1999 00476 (1999-04-01), None
patent: 1171771 (2000-10-01), None
patent: 1381631 (2002-10-01), None
patent: 1382969 (2004-01-01), None
patent: 1 439 393 (2004-07-01), None
patent: 0813654 (1996-05-01), None
patent: 08136548 (1996-05-01), None
patent: 8226918 (1996-09-01), None
patent: WO 93/20447 (1993-10-01), None
patent: WO 97/38314 (1997-10-01), None
patent: WO 00/20860 (2000-04-01), None
patent: 00/62070 (2000-10-01), None
patent: 01/11359 (2001-01-01), None
patent: 02/34776 (2001-10-01), None
patent: 0231507 (2002-04-01), None
patent: WO 02/44736 (2002-06-01), None
patent: 02/086085 (2002-10-01), None
patent: 03/006671 (2003-01-01), None
patent: WO 03/060522 (2003-02-01), None
patent: 03/087830 (2003-10-01), None
patent: WO 2004/029627 (2004-04-01), None
patent: WO 2005/010213 (2005-02-01), None
Agresti, Alan. 1996. An Introduction to Categorical Data Analysis. John Wiley and Sons, Inc. 1996.
“Concentrations of TIMP-1 mRNA Splice Variants and TIMP-1 Protein are Differentially Associated with Prognosis in Primary Breast Cancer” Anieta M. Sieuwerts et al., Clinical Chemistry 53:7, 1280-1288 (2007).
Wu Thomas D. “Analysing gene expression data from DNA microarrays to identify candidate genes” Journal of Pathology, J Pathol 2001, 195:53-65.
Lucentini Jack “Gene Association Studies Typically Wrong” The Scientist Dec. 20, 2004.
Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.J. Rheum.26:2, 251-258.
Khokha R & Waterhouse P (1994) The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction.J.Neurooncol.18, 123-127.
Khokha R, Zimmer MJ, Wilson SM & Chambers AF (1992b) Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo.Clin.Exp.Metastasis10, 365-370.
Kodama S, Yamashita K, Kishi J, Iwata K & Hayakawa T (1989) A sandwich enzyme immunoassay for collagenase inhibitor using monoclonal antibodies.Matrix9, 1-6.
McDougall JR & Matrisian LM (1995) Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 14, 351-362.
Matrisian LM (1992) The matrix-degrading metalloproteinases. Bioessays 14, 455-463.
Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, Abe R, Ueo H & Akiyoshi T (1997) Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma.Br.J.Cancer76, 531-536.
Moutsiakis D, Mancuso P, Krutzsch H, Stetler-Stevenson WG & Zucker S (1992) Characterization of metalloproteinases and tissue inhibitors of metalloproteinase's in human plasma.Connect. Tissue Res.28, 213-230.
Kuska, J. Natl. Cancer Int, 90:564-565, 1998.
Jarzarb et al., Cancer Res., 65: (4) 1587-1597, 2005.
Zweig et al. “Receiver Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine” Clinical Chem. 39/4, pp. 561-577 (1993).
Vincent Leroy et al., “Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis With Chronic Hepatitis C: Comparison with PIIINP and Hyaluronic Acid” American Journal of Gastroenterology, 2004 (pp. 271-279).
Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA (1997) Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.Int. J. Cancer74, 220-223.
Timo Sorsa et al. “Scientific Basis of a Matrix Metalloproteinase-8 Specific Chair-side Test for Monitoring Periodontal and Peri-implant Health and Disease” Annals of New York Academy of Sciences, vol. 878, 1999 pp. 130-140.
Cell and Tumor Biology 14: Protease Inhibitors in Invasion and Metastasis, “Proceedings of the American Association for Cancer Research” , Mar. 1998, pp. 298-299, vol. 39.
Japanese Office Action for Japanese Application No. 2000-611082 dated Jan. 6, 2010 from JPO and English Translation.
U.S. Appl. No. 10/594,999, filed Sep. 29, 2006, Maria Unni Romer et al.
Schrohl Anne-Sofie et al: Tumor tissue concentrations of the proteinase inhibitors Tissue Inhibitor of metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor type 1 are complimentary in determining prognosis in primary breast cancer Mollecullar and Cellular Proteomics vol. 2, No. 3, pp. 164-172 2003 by the American Society of Biochemistry and Molecular Biology, Inc.
Kwaan H C et al: “Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis” British Journal of Cancer (2000) 82(10), pp. 1702-1708.
Simpson Ram et al. Colorectal Dis. 2000; 2:100-5.
Pellegrini P. et al Cancer Immunol Immuunother Sep. 2000; 49 (7) 388:94.
Matsuura E. et al J. Neurol Sci. 2000; 173:45-52.
Jinnin M et al Clin Exp Rheumatol Jul.-Aug. 2002; 20 (4); 539-42.
Katoh N, et al Clin Exp Immunol. 2002 127:283-8.
Tsavellas G, et al Br J Surg. Oct. 2001; 88 (10) 1307-20.
Liefers GJ, et al Histopathology. May 1999; 34 (5):385-90.
Lacroix J, et al Sem Surg Oncol. 2001; 20:252-64.
Calaluce R, et al J. Sug Oncol. 1998; 67:194-202.
Ishida H, et al. Surg Today. 2003; 33 (12) 885-92.
Oberg A, et al. Anticancer Res. Mar.-Apr. 2000; 20 (2B) 1085-91.
Holter-Andersen , Mads N. et al “Plasma levels of Tissue Inhibitor of Metalloproteinases 1 measured during follow up of colorectal cancer patients have clinical value in predicting patient outcome,” Proceedings of the American Association for Cancer Research Annual, vol. 43, Mar. 2002, p. 715.
Takada N. et al “Postoperative sequential changes of serum levels of matrix metalloproteinase and tissue inhibitor of metalloproteinase in Japanese patients with the squamous cell carcinoma of esophagus,” Proceedings of the American Association for Cancer Research Annual, vol. 40, Mar. 1999, p. 346.
Zhou, W. et al “Identifying markers for pancreatic cancer by gene expression analysis,” Database Medline [Online], Abstract of Cancer Epidemiology, Biomarkers & Prevention: A publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, Feb. 1998, vol. 7, No. 2, 109-112, 2 pages.
National Library of Medicine, PubMed Website: “Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients”, Naruo S et al., Int J Urol, vol. 1 No. 3 Sep. 1994, pp. 238-231.
National Library of Medicine, PubMed Website: “Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation”, Henriet P et al, APMIS, vol. 109, No. 1 Jan. 1999, pp. 111-119.
Dialog Information Services, File t59, Cancerlit, acession No. 93691448, Guillem JG et al., “Evaluation of tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic marker of human colorecta
Brünner Nils
Christensen Ib Jarle
Holten-Andersen Mads
Nielsen Hans Jørgen
Stephens Ross
Aksman Stanislaus
Helms Larry R.
Natarajan Meera
Rigshospitalet
Roberts Mlotkowski Safran & Cole P.C.
LandOfFree
Tissue inhibitor of matrix metalloproteinases type-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue inhibitor of matrix metalloproteinases type-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue inhibitor of matrix metalloproteinases type-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169671